Should I buy CONMED Corporation (CNMD) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on CONMED Corporation
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 20 % | +2.4 % | 5 | $40 -21% |
| Stifel | 30 % | +0.9 % | 10 | $55 +9% |
| Piper Sandler | 18 % | -8.5 % | 11 | $45 -11% |
| Needham | 22 % | -20.8 % | 23 | $61 +21% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 5 ratings, only 0 buys, and the median price target ($40) is -21% below the price ($50). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on CNMD, JP Morgan (20% hit rate, 5 scored calls), only targets $40 (call made on May 1, 2026, maturing on May 1, 2027) (-21%) in its most recent call, and $52 (call made on November 6, 2025, maturing on November 6, 2026) (+3%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 5 ratings, 4 are neutral and 1 is a sell.
- Limited upside: the median target is only -21% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on CNMD
Median target $40 (-21%) · 5 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in CONMED Corporation now?
We won't decide for you. The facts: 0% of analysts rate it a buy, median target $40 (-21%), and JP Morgan (most reliable on CNMD, 20%) targets $40. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in CONMED Corporation?
The stated upside is small: the median target ($40) sits just -21% from the price ($50) (most reliable on CNMD: JP Morgan, 20%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is CONMED Corporation still worth investing in?
It depends on the gap between the price ($50) and its estimated value: analysts target $40 on median (-21%), with 0% buys (most reliable on CNMD: JP Morgan, 20%). Cross-check with their real reliability on CNMD and the cautions above. Information, not advice.
What's the main risk in buying CNMD?
Even the most reliable firm on CNMD, JP Morgan (20% hit rate, 5 scored calls), only targets $40 (call made on May 1, 2026, maturing on May 1, 2027) (-21%) in its most recent call, and $52 (call made on November 6, 2025, maturing on November 6, 2026) (+3%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full CONMED Corporation profile (consensus, analyst reliability, price target, performance).